Amyris Inc. (NASDAQ:AMRS) has been given a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company. Amyris’ rating score has improved by 14.2% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokerages have set a one year consensus target price of $2.63 for the company and are predicting that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also given Amyris an industry rank of 28 out of 265 based on the ratings given to related companies.
AMRS has been the topic of several analyst reports. Zacks Investment Research raised Amyris from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Tuesday, August 9th. Singular Research reaffirmed a “buy” rating and issued a $2.80 target price on shares of Amyris in a research report on Wednesday.
Amyris (NASDAQ:AMRS) opened at 0.5289 on Monday. The firm’s market capitalization is $124.30 million. Amyris has a 52 week low of $0.31 and a 52 week high of $2.57. The firm has a 50-day moving average of $0.44 and a 200 day moving average of $0.64.
Amyris (NASDAQ:AMRS) last issued its earnings results on Thursday, August 4th. The company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.06. The company earned $9.60 million during the quarter, compared to analyst estimates of $15.23 million. During the same period in the prior year, the business earned ($0.47) earnings per share. Amyris’s quarterly revenue was up 23.1% on a year-over-year basis. Analysts predict that Amyris will post ($0.20) earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in shares of Amyris by 302.3% in the first quarter. Goldman Sachs Group Inc. now owns 101,704 shares of the company’s stock worth $113,000 after buying an additional 76,423 shares during the period. Geode Capital Management LLC raised its position in shares of Amyris by 11.6% in the first quarter. Geode Capital Management LLC now owns 298,669 shares of the company’s stock worth $331,000 after buying an additional 30,958 shares during the period. Vanguard Group Inc. raised its position in shares of Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Amyris during the first quarter worth approximately $269,000. 35.68% of the stock is currently owned by institutional investors.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.